Biopharmaceutical manufacturer
Appears in 1 story
Manufacturing insulin glargine for Civica under FDA approval
On January 1, 2026, nonprofit Civica Rx launched insulin glargine pens at $55 a box; California debuted its CalRx-branded insulin the same day at the same price. Both undercut branded products by up to 90%: no insurance forms, no rebates, no hidden markups, just one transparent price for anyone, in a market three pharmaceutical giants control with a 90% share.
Updated May 19
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
